Vaccinex, Inc. stock is down -6.16% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 16.67% of the previous 5 November’s closed higher than October.
Vaccinex, Inc. engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials.